Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 31, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries and marketing products in around 170 countries. The filing specifically details transactions executed under a programme initiated on May 6, 2026, which is part of a broader 12-month repurchase plan starting February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period beginning February 4, 2026.
- Specific Programme (May 6, 2026): Up to DKK 11,200,000,010.45 for B shares between May 6, 2026, and February 1, 2027.
- Cumulative Repurchases (since Feb 4, 2026): 30,979,179 B shares at an average price of DKK 281.08, totaling DKK 8,707,673,805 as of August 28, 2026.
- Recent Transactions (Aug 24-28, 2026): 1,050,000 B shares purchased for approximately DKK 317.2 million.
- Treasury Shares: 45,019,876 B shares held, representing 1.0% of total share capital (4,465,000,000 shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the last announcement on August 24, 2026, the company executed five additional transactions between August 25 and August 28, 2026. The average purchase price for these recent transactions ranged from DKK 296.89 to DKK 308.60. The total accumulated value under the specific May 6 programme reached DKK 4,907,673,815, with 16,220,000 shares repurchased under this specific tranche.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period commencing February 4, 2026. The company reaffirms its purpose to drive change to defeat serious chronic diseases, built upon its heritage in diabetes. The filing does not contain specific financial guidance, risk factors, or contingencies beyond the standard execution of the share buyback programme.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total programme (approximately DKK 6.3 billion remaining as of August 28, 2026).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 281.08.
- Review the full transaction details on novonordisk.com for granular daily execution data.
- Check the latest Form 20-F or quarterly reports for operational financial metrics (revenue, profit, cash flow) which are not included in this 6-K.